Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| United States | 69.3 | 70.8 | 71.9 | 0.5 | 0.2 | 57.6 | 50.5 | 42.6 |
| Surgical products | 59.9 | 59.4 | 59.0 | 53.7 | 38.8 | 28.9 | 19.4 | 7.9 |
| Brachytherapy seed | 23.6 | 24.1 | 23.8 | 25.0 | 28.8 | 33.5 | 34.9 | 36.4 |
| Europe | 7.4 | 7.7 | 7.5 | 6.1 | 5.1 | 3.0 | 1.9 | 0.8 |
| Total revenues [+] | 82.6 | 82.7 | 82.2 | 78.3 | 67.4 | 62.2 | 54.1 | 44.3 |
| Products | | | | 77.2 | | | | |
| Revenue growth [+] | -0.2% | 0.7% | 4.9% | 16.3% | 8.3% | 15.0% | 22.2% | 32.8% |
| United States | -2.2% | -1.4% | 14072.2% | 213.0% | -99.7% | 14.1% | 18.7% | 28.8% |
| Surgical products | 0.9% | 0.6% | 10.0% | 38.4% | 34.2% | 49.2% | 144.6% | |
| Brachytherapy seed | -2.0% | 1.4% | -4.9% | -13.3% | -14.1% | -3.9% | -4.1% | 9.1% |
| Europe | -3.9% | 1.6% | 22.9% | 19.3% | 72.8% | 55.0% | 151.4% | |
| Other foreign countries | 73.3% | 52.0% | -23.5% | 88.0% | 34.4% | 7.1% | 67.8% | |
| Cost of goods sold | 52.0 | 50.1 | 49.2 | 45.0 | 36.3 | 32.0 | 27.8 | 23.8 |
| Gross profit | 30.5 | 32.7 | 33.0 | 33.4 | 31.1 | 30.2 | 26.3 | 20.5 |
| Gross margin | 37.0% | 39.5% | 40.2% | 42.6% | 46.2% | 48.6% | 48.7% | 46.3% |
| Selling, general and administrative | 22.3 | 22.7 | 24.0 | 22.0 | 20.5 | 19.1 | 20.0 | 19.7 |
| Research and development | | | | 2.2 | 1.3 | 1.4 | 0.8 | 3.6 |
| Other operating expenses | 4.5 | 4.5 | 4.9 | 3.4 | 72.6 | 2.4 | 1.0 | 0.5 |
| EBITDA [+] | 11.7 | 12.7 | 11.3 | 12.7 | -57.7 | 13.5 | 10.6 | 3.5 |
| EBITDA growth | -8.3% | 12.6% | -10.9% | -122.0% | -527.8% | 26.7% | 201.9% | -439.1% |
| EBITDA margin | 14.1% | 15.4% | 13.7% | 16.2% | -85.7% | 21.7% | 19.7% | 8.0% |
| Depreciation | 7.9 | 7.2 | 7.2 | 6.9 | 3.2 | 4.3 | 4.7 | 6.3 |
| EBITA | 3.8 | 5.5 | 4.1 | 5.8 | -60.9 | 9.2 | 6.0 | -2.8 |
| EBITA margin | 4.6% | 6.6% | 5.0% | 7.3% | -90.5% | 14.8% | 11.1% | -6.3% |
| Amortization of intangibles | | | | | 2.4 | 1.9 | 1.4 | 0.5 |
| EBIT [+] | 3.8 | 5.5 | 4.1 | 5.8 | -63.3 | 7.3 | 4.6 | -3.3 |
| EBIT growth | -31.5% | 34.5% | -29.0% | -109.1% | -962.4% | 59.0% | -240.4% | -58.8% |
| EBIT margin | 4.6% | 6.6% | 5.0% | 7.3% | -94.0% | 11.8% | 8.5% | -7.4% |
| Non-recurring items [+] | | | 0.2 | 0.0 | | | 0.6 | 33.4 |
| Loss (gain) on sale of assets | | | | 0.0 | | | | |
| Interest income, net [+] | 0.1 | 0.2 | 0.1 | -0.8 | 0.2 | 1.5 | 1.1 | 1.3 |
| Interest expense | 0.6 | 0.7 | 1.0 | 0.9 | 0.8 | 0.7 | 0.4 | 0.2 |
| Interest income | 0.1 | 0.2 | 0.1 | 0.0 | 1.1 | 2.2 | 1.5 | 1.4 |
| Other income (expense), net | 0.0 | 0.0 | 0.3 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | 3.3 | 5.0 | 3.3 | 4.9 | -63.1 | 8.8 | 5.2 | -35.4 |
| Income taxes | 1.1 | 1.9 | 1.2 | 1.8 | -4.5 | 3.2 | -1.7 | -6.4 |
| Tax rate | 34.7% | 38.3% | 37.3% | 37.4% | 7.2% | 36.3% | | 18.1% |
| Net income | 0.0 | 0.0 | 0.0 | 3.1 | -58.5 | 5.6 | 6.9 | -29.0 |
| Net margin | 0.0% | 0.0% | 0.0% | 3.9% | -86.9% | 9.1% | 12.7% | -65.5% |
| |
| Basic EPS [+] | $0.00 | $0.00 | $0.00 | $0.09 | ($1.77) | $0.17 | | |
| Growth | | | -100.0% | -105.2% | -1140.0% | | | |
| Diluted EPS [+] | $0.00 | $0.00 | $0.00 | $0.09 | ($1.77) | $0.17 | | |
| Growth | | | -100.0% | -105.2% | -1146.2% | | | |
| |
| Shares outstanding (basic) [+] | 31.5 | 33.4 | 33.3 | 33.1 | 33.1 | 33.1 | | |
| Growth | -5.9% | 0.5% | 0.3% | 0.2% | -0.1% | | | |
| Shares outstanding (diluted) [+] | 32.2 | 33.8 | 33.5 | 33.3 | 33.1 | 33.3 | | |
| Growth | -4.9% | 1.0% | 0.6% | 0.6% | -0.7% | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|